This may be due to LOXL2 forming a physical barrier to inhibit the diffusion of gemcitabine by increasing fibrous collagen and then increasing ECM stiffness, or it may be due to the collapse of blood vessels in the tumor caused by LOXL2, which can limit the transport of gemcitabine into the tumor interior 342. This evidence concerns the gene LOXL2 and neoplasm.